GSK stock
GSKNYSEGSK plc, HealthcareISIN US37733W2044
69Score 69 out of 100, Neutral
Price and trend
63 / 100
Price history
+5.3% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 3.4% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 17% below its 52-week high. Largest decline in 20 years: 54% (April 2007 to March 2009).
Chart figures for advanced users
- SMA 50$49.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$52.40
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$46.11
- The lowest closing price of the last twelve months.
- Resistance$61.18
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GSK plc belongs to the Drug Manufacturers (General) industry (United Kingdom) and, with a market value of $101.51B, is number 14 of 27 companies in its industry on MEQIRI.
- American depositary receipt (ADR): 1 ADR = 2 shares.
- In fiscal 2025 it reported revenue of $43.3B (up 4.1% year on year) and earnings of $7.58B (up 122%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 156 of 702 in Healthcare, median 53.
- The P/E is 17.9 (Drug Manufacturers (General) median 25.7, own median of recent years 14).
- Our model puts fair value at $85.48, with the price 41% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 41% below the fair value of $85.48.Valuation 75
- High return on capitalReturn on invested capital 23.8% in fiscal 2025, Drug Manufacturers (General) median 13.4%.Profitability 81
- Earnings turn into cashFree cash flow 157% of earnings over the last 12 months.Fundamentals 95
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and profitability, while growth holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 70 to 69.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $65.75 and expensive above $122.11 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $98.32 (cash-flow model) and $72.64 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $77.12, at 7.8% it would be $98.03.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.1% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating 24%, net 17%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 28 Oct 2026above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 3.63+0.8%
- Revenue
- $45.42B+0.5%
- Earnings per share
- 3.77−1.4%
- Revenue
- $47.2B−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.4%GSK reconfirms full year 2026 guidance, expects sales and operating profit in the upper half of the range, but EPS growth only in the lower half due to higher interest expense and one-off charges.
“Given our operating momentum and launch progress, we are pleased to reconfirm 2026 guidance today.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at GSK
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Novo NordiskNOVO-B.CO $180.19B79
- PfizerPFE $164.33B60
- Bristol-Myers SquibbBMY $127.39B70
- SanofiSAN.PA $116.8B67
- Chugai Pharmaceutical4519.T $73.66B78
- BayerBAYN.DE $61.57B53
- Otsuka Holdings4578.T $40.24B78
- BiogenBIIB $37.03B60
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = £0.7544)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.